Athersys, Inc. (NASDAQ:ATHX)

CAPS Rating: 2 out of 5

Results 1 - 18 of 18

Recs

0
Member Avatar Deepvaluestocks (48.85) Submitted: 5/15/2015 9:42:34 PM : Underperform Start Price: $1.25 ATHX Score: -5.32

Way overpriced given negative news flow because people are holding out a false hope that Japan will come to rescue

Recs

1
Member Avatar zzlangerhans (99.80) Submitted: 5/13/2015 1:24:01 AM : Underperform Start Price: $1.39 ATHX Score: +5.66

Of all the stocks to cling to their residual valuation after a negative binary catalyst, Athersys seems to have the least justification. Now that their MultiStem soup has failed in both ulcerative colitis and ischemic stroke, it's hard to see how anyone could consider this concoction to have any kind of therapeutic potential. In order to take advantage of the recent trend of stocks continuing to bleed in the days and weeks after a failed trial, I established a quick short in Athersys at 1.4 which led to a respectable profit last month. Mysteriously, the share price rebounded from 1.2 and I re-initiated the short with 5000 shares at 1.41 yesterday. My pessimism was further validated when the company announced in the AH that Pfizer had terminated the collaboration on MultiStem for ulcerative colitis. The stock dipped in the AH and the early part of today's trading session, then inexplicably rebounded once again. I added 1600 shares to the short and am now at 6600 with a cost basis of 1.41.

So what could longs be expecting from this stock at this price? The market cap is 112M, cash is 36M as of the end of March, and MultiStem is inert. Of course, Athersys is mouthing the usual post hoc inanities about their failed trial and there's some kind of phase II trial of MultiStem in myocardial infarction going on, but could anyone seriously believe this will go anywhere? The only thing that worries me about this short is the ever present risk of forced covering, which is what caused me to lose on my short of the scam Novogen. Otherwise, I'm fairly confident I'll be adding to my gains on the Athersys play.

Recs

0
Member Avatar pchop12316 (77.38) Submitted: 5/12/2015 12:14:03 PM : Underperform Start Price: $1.35 ATHX Score: +3.63

not convinced

Recs

0
Member Avatar NuclearSteve (69.51) Submitted: 4/24/2015 3:20:09 PM : Underperform Start Price: $1.29 ATHX Score: -1.74

Garbage stem cell with 2 failures. Short into oblivion. CEO is a crook and I saw evidence the company uses promoters. They tricked me once on the long side.... now I will get my revenge by shorting them on CAPS. Muhahahaha!

Recs

0
Member Avatar usubanas (99.78) Submitted: 4/24/2015 12:06:32 PM : Underperform Start Price: $1.28 ATHX Score: -2.62

Should keep dropping to penny status. Reload.

Recs

0
Member Avatar stemcells2011 (93.58) Submitted: 3/4/2015 2:42:03 PM : Underperform Start Price: $2.91 ATHX Score: +54.83

I have been betting on stem cell related treatments for some years now as you can probably tell. I have been disappointed and lost money on almost every said trade/investment.

I hope I am proven wrong now and that this company succeeds. I hope I lose hundreds of points on this caps only pick.

Recs

0
Member Avatar ravngm (< 20) Submitted: 10/23/2014 2:11:59 PM : Outperform Start Price: $1.31 ATHX Score: -3.48

Pipeline. Upside of business. Risky....

Recs

1
Member Avatar Dublin43016 (< 20) Submitted: 2/22/2014 10:51:56 AM : Outperform Start Price: $4.03 ATHX Score: -82.07

1. Recent regulatory changes to accelerate regenerative medicine use in Japan, will allow faster development of their products. CEO has already made several trips so as to get his ducks in a row.

2.Second quarter results on phase II study on Ulcerative Colitis done by Pfizer using ATHX's their multistem cells.

3. Mid year results on the use of multistem on a phase II study in the use of the cells for the treatment of ischemic stroke a potential 20 billion market.

Recs

1
Member Avatar bburr4307 (< 20) Submitted: 1/30/2014 9:02:27 PM : Outperform Start Price: $3.84 ATHX Score: -85.16

ATHX is a very interesting bet in my opinion, because of the impact their product has of changing the medical world and treatments as we know it. I've been struggling with whether 3D printing might have a profound effect in the medical world also, and though I think 3D printing will be a game changer in other areas and hold DDD stock, I think the path that ATHX is on with their stem cell product is better and much more pratical in the short term and long term due to the moral, ethical, and legal complications that will be associated with 3D printing in the medical field. The product that ATHX is and has been working on is truly a remarkable product that has endless possibilities of transforming medical science and the curing of devistating diseases as we know it and as long as the company plan continues on it's course I plan to be invested. In fact, as of now, if I had only 1 choice od what stock to own this would be my pick. Next bump up should be around April when the ongoing trials finish up, and Japan looks to be the first area of opportunity to put their product to use. I've been invested and following ATHX for over a year and never have been as excited about a stock as this one. I see years of growth in the future as new opportunities to expand the usage of their system become available. As a note, due to the type of system they are using, there should not be the moral or ethical questions related to the stem cell therapy they propose. I'm in for the long haul as I see this becoming a 1000 bagger in the future.

Recs

0
Member Avatar alfredogonzalez6 (< 20) Submitted: 8/20/2013 7:27:39 PM : Outperform Start Price: $1.80 ATHX Score: -55.03

With them heading into stage II in either 1Q/2Q of 2014, everything looks promising, so definitely in it for the long run.

Recs

0
Member Avatar itsthedudeguy (40.26) Submitted: 4/9/2013 6:25:42 AM : Outperform Start Price: $1.73 ATHX Score: -59.19

20 mil in R&D in 2012

Recs

0
Member Avatar toegar2000 (54.47) Submitted: 3/2/2013 10:19:00 AM : Outperform Start Price: $1.48 ATHX Score: -50.61

Good up and coming product line in the works.

Recs

0
Member Avatar JaiYen (< 20) Submitted: 1/26/2012 1:27:32 PM : Outperform Start Price: $1.88 ATHX Score: -89.95

Great place to park speculative money. Anything stem cell has sex appeal that could really pop on positive news. Partnership with PFE says a lot about the science behind this company and so far management seems very savvy about locking up patents and forming strategic partnerships. This is my BIG speculative play.

Recs

0
Member Avatar atarheelfool (< 20) Submitted: 8/3/2011 9:47:17 PM : Outperform Start Price: $2.54 ATHX Score: -118.12

Connection to Pfizer shows legitimacy. Management is top notch and patents for stem cell research puts this Athersys in a great position to do well for a long time.

Recs

0
Member Avatar Zo3adams (< 20) Submitted: 7/25/2011 1:00:50 AM : Outperform Start Price: $2.71 ATHX Score: -110.06

Waiting patiently for a very successful clinical trial to see a big jump. Long term game, this small company is ran by expert-in-field scientific talent and very likely to strike a home-run

Recs

0
Member Avatar London2485 (59.89) Submitted: 3/10/2011 5:26:09 PM : Outperform Start Price: $2.48 ATHX Score: -110.19

This is a real money stock as well, purchased right around this amount very recently.

Their flagship product, MultiStem, appears to have application in a wide range of areas, from leukemia to stroke. The Phase I trials are complete, and the product has been pretty successful in stroke victims. The fact that it's efficacy is compromised by how soon it can administered to the stroke victim makes little impact. ALL interventions with stroke victims lose efficacy over time.

However, the positive results have so far only been seen in animals. The company will probably need to raise further capital.

If you can tolerate high risk, consider adding Athersys (it's my highest risk stock in my real life portfolio).

Recs

0
Member Avatar ebitdat (< 20) Submitted: 9/16/2010 8:21:09 PM : Outperform Start Price: $2.99 ATHX Score: -142.97

Product appears commercially viable and already has a nice partnership agreement. Upcoming presentation of phase I data in heart patients should provide a nice boost, and an opportunity to gauge interest from other partners.

Results 1 - 18 of 18

Featured Broker Partners


Advertisement